Fudge and other experts call for the development of a variety of new coronary pneumonia vaccine

Four scientists, including Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), have published a new article outlining the challenges to be overcome in developing a new coronary pneumonia vaccine over the next year or two,media reported. Scientists believe that it is not one vaccine that is needed to survive the pandemic and get back to normal.

Fudge and other experts call for the development of a variety of new coronary pneumonia vaccine

“We’re experiencing a series of unprecedented events, and the disease has spread globally, with more infections in a short period of time than any other infection in modern times,” said Larry Corey, a professor of vaccines and infectious diseases at the Hodgson Cancer Research Center in Seattle. To overcome the challenges before us, each of us needs to be the best new coronavirus vaccine development requires creativity, cooperation and commitment to save as many lives as possible as quickly as possible. “

In addition to Fauci and Corey, the authors include Francis Collins, director of the National Institutes of Health (NIH), and John Mascola, director of the NIAID Vaccine Research Center. This article discusses several issues that need to be addressed before the vaccine can be effectively deployed. In addition to the issue of immunization and reinfection, the article also raises the subject of controversial human challenge trials.

The Human Challenge Trials are a rarely used vaccine development strategy through which healthy volunteers are deliberately exposed to an infectious agent. There have been calls for human challenge trials in the current context to accelerate the vaccine development process.

In the context of the development of a new coronavaccine, the four authors of this article express concern about the safety and practicality of human challenge trials. They argue that effectiveness for young, healthy adults does not necessarily translate into other risk demographics, and that the implementation of this strategy must be evaluated by an independent panel of ethicists.

The article also discusses the various vaccines currently being developed and recommends that several different successful vaccines be eventually developed to effectively meet global needs. “No single vaccine or vaccine platform can meet global demand, so a multi-pronged strategic approach is absolutely critical.” “

Professor Kim Mulholland, a vaccine scientist at the Murdoch Children’s Institute in Australia, echoed this sentiment in a recent media interview. He argues that because many of the vaccines being developed are based on similar scientific assumptions, if one vaccine succeeds, others will succeed. If there are several successful vaccines, they can be deployed more quickly around the world.

The article concludes with a call for harmonious global cooperation in vaccine development, production and distribution.

“The complete development path of an effective SARS-CoV-2 vaccine will require industry, government, and academia to work together in an unprecedented way and each to increase their respective strengths,” the article reads. The pattern of all these projects already exists, and if we are to successfully return to the social interaction before the outbreak of the new coronavirus within the necessary time, we must quickly put these ideas into action. “